Skip to content

Evaluation of the oral Nicorandil effect on reducing the contrast-induced

Evaluation of the oral Nicorandil effect on reducing the contrast-induced nephropathy incidence in cardiac catheterization patients: a randomized controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210620051631N1
Enrollment
344
Registered
2021-12-19
Start date
2021-12-22
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac catheterization.

Interventions

Intervention 1: Intervention group: from 2 hours before to 24 to 48 hours after the procedure, oral nicorandil 10 mg 3 times a day, and intravenous normal saline from 2 hours before to 6 hours after t

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Based on the risk score,Have a moderate risk or at least two risk factors for contrast nephropathy. EF less than 40 Diabetes mellitus. Blood pressure above 140/90 mm Hg, Renal failure (GFR) less than 60 No pregnancy (basal serum creatinine above 1.5 mg / dl) Minimum age 18

Exclusion criteria

Exclusion criteria: Pregnancy Pulmonary edema Cardiogenic shock Multiple myeloma Acute renal failure ESRD(GFR<15 mg/dl) Allergy to media contrast Nicorandil allergy Facing media contrast in the last 7 days NAC and metformin and dopamine and sodium bicarbonate and mannitol and phenol dopam in the last 48 hours

Design outcomes

Primary

MeasureTime frame
Laboratory banksHb, FBS, HCT, TG, LDL, HDL,ChoL. Timepoint: The first step at the beginning of the study. Method of measurement: Sampling.

Secondary

MeasureTime frame
Serum creatinine and creatinine clearance and BUN. Timepoint: It is measured 24 to 48 hours after the procedure. Method of measurement: Protocol based analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Abdollahimoghaddam

Mashhad University of Medical Sciences

alavisadegh157@gmail.com+98 51 3843 6827

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026